

in association with



promoted by



With the patronage of



1 SOHO ITALY SCHOOL ACUTE LEUKEMIA

Clinical And Biological

www.sohoitaly.it

JOIN US!



@sohoitaly

#SOHOitLEUKEMIA

15 16 17 March 2021

**C. Cerchione N. Daver A. De La Fuente E. Jabbour H. Kantarjian
M. Konopleva F. Locatelli G. Martinelli F. Ravandi**

Virtual Event

Registration



Organizing secretariat



www.proeventi.it

20 CME (ECM) HEMATOLOGISTS, ONCOLOGISTS, PATHOLOGIST, BIOLOGISTS



SCHOOL **ACUTE LEUKEMIA**

Clinical And Biological

15 16 17 March 2021

Virtual Event

Presidents:

Cerchione C, Martinelli G, Kantarjian H

Scientific Board:

Cerchione C, Martinelli G, Locatelli F, Daver N, De La Fuente A, Jabbour E, Kantarjian H, Konopleva M, Ravandi F

Scientific Secretariat:

Cerchione C, Martinelli G, Locatelli F, Daver N, Jabbour E, Kantarjian H, Konopleva M, Ravandi F, Giannini B, Musuraca G, Norata M

Big Faculty:

Cerchione C, Martinelli G, Locatelli F, Daver N, Jabbour E, Kantarjian H, Konopleva M, Buccisano F, Ferrari A, Foà R, Galimberti S, Gottardi M, Iacobucci I, Isidori A, Lanza F, Martelli MP, Olivieri A, Pagano L, Papayannidis C, Quintarelli C, Rambaldi A, Ribera J, Rosti G

Young Faculty

Boccalatte F, Fiorentini A, Fontana MC, Ghelli A, Gheti M, Imbrogno E, Marconi G, Mosquera A, Nanni J, Padella A, Piemontese S, Raimondi V, Sartor C, Silic-Benussi M, Simonetti G,

Day 0

15 march 2021

- 18.15 - 18.30 Welcome and Presentation of the School of Acute Leukemia
SOHO Italy Presidents:
[C. Cerchione](#), [G. Martinelli](#), [H. Kantarjian](#)
- 18.30 - 19.00 Lecture: How I manage Acute Myeloid Leukemia in USA- [H. Kantarjian](#)
- 19.00 - 19.30 Lecture: How I manage Acute Myeloid Leukemia in Europe - [G. Martinelli](#)
- 19.30 - 20.00 Lecture: How I manage Acute Lymphoblastic Leukemia in USA - [H. Kantarjian](#)
- 20.00 - 20.30 Lecture: How I manage Acute Lymphoblastic Leukemia in Europe - [G. Martinelli](#)
- 20.30 - 21.00 Lecture: How I manage pediatric Acute Leukemias - [F. Locatelli](#)

Day 1

16 March 2021

Frontal Big Faculty Session

- 08.30 - 08.50 Opening and introduction to the project:
[C. Cerchione](#) - [G. Martinelli](#)

Acute Lymphoblastic Leukemia

Biology and MRD Session in ALL: [C. Papayannidis](#), [A. Ferrari](#), [C. Quintarelli](#)

- 08.50 - 09.10 Impact of new opportunities in ALL biology - [C. Quintarelli](#)

- 09.10 - 09.30 Importance of MRD in ALL – [C. Papayannidis](#)
- 09.30 - 09.50 Adult Triple Negative B-ALL fusion landscape: new basis for potential treatments – [A. Ferrari](#)
- 09.50 - 10.00 break

Biology Session AML – I. Iacobucci, F. Buccisano, G. Rosti

- 10.00 - 10.20 New insights into AML Biology – [I. Iacobucci](#)
- 10.20 - 10.40 Molecular Pathogenesis of AML – [S. Galimberti](#)
- 10.40 - 11.00 Importance of MRD assessment and impact on treatment – [F. Buccisano](#)

Clinical Session ALL 1 – G. Martinelli, F. Locatelli, F. Lanza, R. Foà

- 11.00 - 11.20 How we manage ALL in daily practice in Europe – [G. Martinelli](#)
- 11.20 - 11.40 Role of monoclonal antibodies in relapsed/refractory ALL – [F. Lanza](#)
- 11.40 - 12.00 Near future of ALL – [R. Foà](#)
- 12.00 - 12.20 CAR Cytokine Induced Killer (CIK) Cells for Relapsed B-Cell Acute Lymphoblastic Leukemia – [A. Rambaldi](#)
- 12.20 - 12.50 Discussion
- 12.50 - 14.10 **Lunch Break**

Clinical Session ALL 2 – H. Kantarjian, E. Jabbour, M. Konopleva, A. De La Fuente

- 14.10 – 14.30 Immunotherapy in adult and elderly ALL – [E. Jabbour](#)
- 14.30 – 14.50 How I manage Ph-positive ALL – [E. Jabbour](#)
- 14.50 – 15.10 How I manage Early T-cell precursors ALL and Ph-like ALL – [M. Konopleva](#)
- 15.10 – 15.30 CAR-T Clinical Trials in ALL – [F. Locatelli](#)
- 15.30 – 15.50 Near future of CAR-T based approach in ALL – [J. Ribera](#)

Acute Myeloid Leukemia

Clinical Session AML 1 – C. Cerchione, N. Daver, F. Ravandi

- 15.50 – 16.10 How we manage AML in daily practice in Europe – [G. Martinelli](#)
- 16.10 – 16.30 How we integrate immunotherapy and target-therapies in AML management – [N. Daver](#)
- 16.30 – 16.50 Optimizing FLT3 inhibitor use in AML in 2021 – [N. Daver](#)
- 16.50 – 17.10 Novel antibodies in AML: new target therapies are possible – [F. Ravandi](#)
- 17.10 – 17.30 Role of IDH inhibitors in AML – [M.P. Martelli](#)
- 17.30 – 17.50 Environment mediated drug resistance in AML – [C. Cerchione](#)
- 17.50 – 18.00 Break

Clinical Session AML 1 - A. Isidori, M. Gottardi, A. Olivieri, A. Lucchesi

- 18.00- 18.20 Elderly AML: present and future - [A. Isidori](#)
- 18.20 - 18.40 How we manage BDPCN as new entity - [L. Pagano](#)
- 18.40 - 19.00 Role of allogenic transplant in AML - [A. Olivieri](#)
- 19.00 - 19.20 Role of maintenance in AML - [M. Gottardi](#)

Near future of Acute Leukemias - C. Cerchione, G. Martinelli, H. Kantarjian

- 19.20 - 19.40 Near future of Acute Leukemias in Europe - [G. Martinelli](#)
- 19.40 - 19.50 Take Home Messages and Conclusions of Day 1 -
[C. Cerchione](#), [G. Martinelli](#)

Day 2

17 March 2021

Young session

Selected oral presentations with project presentations in different categories

1st Session: Biology of Acute Leukemias

**Ferrari A, Iacobucci I, S. Galimberti, C. Quintarelli,
C. Papayannidis, G. Martinelli, C. Cerchione, A. Romano**

- 09.00 - 09.30 Intracellular and biofluid metabolomics distinguishes two subgroups of NPM1-mutant Acute Myeloid Leukemia with diverse genomic and transcriptomic signatures
[G. Simonetti \(Meldola, FC\)](#)
- 09.30 - 10.00 MTORC inhibitor decrease G6PD levels and triggers cell death in T-Lymphoblastic Leukemia T-ALL) cells
[M. Silic-Benussi \(Padova\)](#)

- 10.00 - 10.30 Pharmacological inhibition of WIP1 sensitizes Acute Myeloid Leukemia Cells to the MDM2 inhibitor Nutlin-3A - [MC. Fontana \(Meldola, FC\)](#)
- 10.30 - 11.00 Understanding the role of the ATR-Chk1 pathway in the response to Doxorubicin-induced DNA damages in Acute Lymphoblastic Leukemia
[A. Ghelli Luserna Di Rorà \(Meldola, FC\)](#)
- 11.00 - 11.30 Exploring PVT1/CIRCPVT1 roles and their regulation through bromodomain and extra-terminal motif protein inhibitors in Acute Myeloid Leukemia
[M. Ghetti \(Meldola, FC\)](#)
- 11.30 - 12.00 PALB2 copy number loss associates with poor prognosis AML and suggests novel therapeutics strategies targeting the DNA repair pathway
[A. Padella \(Meldola, FC\)](#)
- 12.00 - 12.30 Epigenetic regulation of Acute Lymphoblastic Leukemia
[F. Boccalatte \(New York, USA\)](#)
- 12.30 - 13.00 Open Discussion:
Questions and answers and discussion for future papers
- 13.00 - 14.00 **Lunch Break**

3rd Session: Clinical of Acute Leukemias

H. Kantarjian, N. Daver, E. Jabbour, M. Konopleva, F. Ravandi, F. Locatelli, J. Ribera, A. Lucchesi, G. Musuraca, R. Foà, M. Gottardi, MP. Martelli, A. Olivieri, A. Isidori, F. Buccisano, F. Lanza, L. Pagano, G. Rosti, G. Martinelli, C. Cerchione, A. Romano

- 14.00 - 14.30 Allogeneic hematopoietic stem cell transplantation in patients older than 65 years with AML and MDS: a 15-year monocentric experience - [S. Piemontese \(Milano\)](#)
- 14.30 - 15.00 Good Risk AML, a heterogeneous group: analysis of outcome according to molecular subgroups
[A. Fiorentini \(Ancona\)](#)
- 15.00 - 15.30 Production of anti CD19 CAR-T cells and rational design of a trial testing anti CD19 CAR-T cell effectiveness in adult with CD19 positive Acute Lymphoblastic Leukemia in complete remission with measurable residual disease
[G. Marconi \(Meldola, FC\)](#)
- 15.30 - 16.00 Development of a novel pharmacological strategy to overcome resistance to ABT-199 in Acute Myeloid Leukemia - [V. Raimondi \(Padova\)](#)
- 16.00 - 16.30 A preliminary analysis of FLAM (Italian non-interventional multi-center study of FLT3 mutated AML patients): FLT3 receptor gene mutational analysis and FLT3 inhibitors administration in the real-life clinical practice
[J. Nanni \(Bologna\)](#)
- 16.30 - 17.00 Oncorelief: a digital guardian angel enhancing cancer patient's wellbeing and health status improvement following treatment
[E. Imbrogno \(Meldola, FC\)](#)

- 17.00 - 17.30 Baseline CD22 mean fluorescent intensity and Inotuzumab ozogamic for relapsed/refractory B-CELL Acute Lymphoblastic Leukemia
C. Sartor (Bologna)
- 17.30 - 18.00 Personalized survival prediction of patients with Acute Myeloblastic Leukemia using gene expression profiling
A. Mosquera (Santiago de Compostela, Spain)
- 18.00 - 18.30 Questions and answers and discussion for future papers
- 18.30 - 18.45 Conclusion and next steps

in associaton with



promoted by



**SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA**

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Istituto di Ricovero e Cura a Carattere Scientifico



supported by an unrestricted educational grant form



Follow us!

The use of social media is extremely important to build a stronger relationship and to improve the interaction between speakers and attendees, so do not forget to use them!

Our official hashtag is #SOHOitLEUKEMIA

You can use it on Facebook, Twitter, Instagram and LinkedIn

Put your like on our social pages and follow us!

You can tweet with:

@sohoitaly
@SOHOitLEUKEMIA
@SocietyofHemOnc
@IRSTufficiale
@MDAndersonNews
@pro_eventi
@GMartinelli2
@DottorClaudio

Follow us!



#SOHOitLEUKEMIA

in association with



society of hematologic oncology

Promoted by



SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Istituto di Ricovero e Cura a Carattere Scientifico

ISTITUTO
ROMAGNOLO
PER LO STUDIO
DEI TUMORI
DINO AMADORI



SCHOOL ACUTE LEUKEMIA

Clinical And Biological